文献速递系统性红斑狼疮

阿尼鲁单抗治疗系统性红斑狼疮在真实世界临床实践中的安全性和有效性:LOOPS注册研究

Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

这项回顾性观察研究纳入开始阿尼鲁单抗治疗的系统性红斑狼疮患者,主要终点为起始治疗后26周保留率,45例随访≥12周者按未达LLDAS组和轻微复发组分析12周内安全性和有效性,并经倾向评分逆概率治疗加权后与标准治疗组比较。26周保留率为89.7%,两组的糖皮质激素剂量和SELENA-SLEDAI评分均显著下降,阿尼鲁单抗组糖皮质激素剂量和SLEDAI评分显著低于标准治疗组或糖皮质激素增量组,LLDAS达标率无显著差异。

要点

  • 阿尼鲁单抗26周保留率为89.7%。
  • 12周时未达LLDAS组和轻微复发组的LLDAS达标率分别为42.9%和66.7%。
  • 阿尼鲁单抗组糖皮质激素剂量和SLEDAI评分显著低于标准治疗组或糖皮质激素增量组,LLDAS达标率无显著差异。

核心结论

  • 起始阿尼鲁单抗治疗26周后约90%的患者仍在治疗。
  • 阿尼鲁单抗可能在不启动糖皮质激素的情况下降低疾病活动度并减少糖皮质激素剂量,尤其在达到LLDAS后出现轻微复发的患者中。

研究设计与样本

  • 回顾性观察研究,纳入开始阿尼鲁单抗治疗的SLE患者。
  • 主要终点为起始阿尼鲁单抗治疗后26周保留率。
  • 45例随访12周及以上的患者按未达LLDAS组和轻微复发组分析至治疗起始后12周的安全性和有效性。
  • 经倾向评分逆概率治疗加权(PS-IPTW)校正后,比较轻微复发组与标准治疗组(加用糖皮质激素或免疫抑制剂)的安全性和有效性。

主要发现

  • 阿尼鲁单抗26周保留率为89.7%。
  • 12周时LLDAS达标率在未达LLDAS组为42.9%,在轻微复发组为66.7%。
  • 两组中糖皮质激素剂量和SELENA-SLEDAI评分均显著下降。
  • 与标准治疗组或糖皮质激素增量组相比,阿尼鲁单抗轻微复发组的糖皮质激素剂量和SLEDAI评分显著更低,LLDAS达标率无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the safety and efficacy of anifrolumab in patients with systemic lupus erythematosus (SLE) classified based on the Lupus Low Disease Activity State (LLDAS) in real-world clinical practice. METHODS: This retrospective observational study involved SLE patients who started anifrolumab therapy. The primary end point was the retention rate over 26 weeks after initiating anifrolumab therapy; 45 patients followed up for 12 weeks or longer were analysed in the following groups to determine the safety and efficacy up to week 12 after treatment initiation: (i) non-LLDAS achievement group and (ii) minor flare group. Safety and efficacy were compared between the minor flare group and the standard of care (SoC) group (treated by adding glucocorticoids [GCs] or immunosuppressants) after adjustment with inverse probability of treatment weighting using propensity score (PS-IPTW). RESULTS: The retention rate of anifrolumab was 89.7% at week 26.The LLDAS achievement rates at week 12 were 42.9% and 66.7% in the non-LLDAS achievement and minor flare groups, respectively. In both groups, GC doses and SELENA-SLEDAI score significantly decreased. When the anifrolumab group with minor flare was compared with the SoC group or the GC dose increase group, the GC dose and SLEDAI score were significantly lower in the anifrolumab group than in either of the other groups; there was no significant difference in LLDAS achievement. CONCLUSION: At week 26 after initiating anifrolumab therapy, ∼90% of patients remained on therapy. Anifrolumab might lower disease activity without initiating GCs and reduce GC doses, especially in patients who experience minor flares after LLDAS achievement.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Miyazaki Y, Funada M, Nakayamada S, et al. Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registry. Rheumatology (Oxford). 2024. PMID: 37934129. doi:10.1093/rheumatology/kead568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。